MLN8237 (0.5 ¦ÌM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 ¦ÌM), involving the higher induction of TAp73¦Â, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment.

June 21, 2017

prudect name : MLN8237 (0.5 ¦ÌM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 ¦ÌM), involving the higher induction of TAp73¦Â, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment.
MLN8237 (Alisertib)

Synonyms: CAS NO: 1028486-01-2Molecular Formula: C₂₇H₂₀ClFN₄O₄Molecular Weight: 518.92Purity: 98% minSolubility: In DMSOStorage: -20°C

web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18528512/